Clinical Trials Logo

Carcinoma, Hepatocellular clinical trials

View clinical trials related to Carcinoma, Hepatocellular.

Filter by:

NCT ID: NCT05970666 Recruiting - Clinical trials for Hepatocellular Carcinoma

Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma

Start date: November 15, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of TACE combined with adebrelimab and bevacizumab transformation in unresectable hepatocellular carcinoma

NCT ID: NCT05970159 Recruiting - Clinical trials for Hepatocellular Carcinoma

Impact of Preoperative Serum Albumin Level on Postoperative Outcomes in Chinese HCC Patients Treated With Surgery

REAL
Start date: August 2023
Phase:
Study type: Observational

This is an observational and retrospective cohort study to evaluate the impact of the preoperative serum albumin concentration on postoperative outcomes among hepatocellular carcinoma (HCC) patients who received hepatectomy or liver transplantation.

NCT ID: NCT05967143 Recruiting - Clinical trials for Unresectable Hepatocellular Carcinoma (HCC)

Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors (SIRtain Registry)

SIRtain
Start date: June 19, 2023
Phase:
Study type: Observational [Patient Registry]

This registry seeks to prospectively gather a large repository of comprehensive observational data reflecting routine use of SIR-Spheres in patients diagnosed with unresectable HCC or unresectable liver metastases from mCRC refractory to or intolerant to chemotherapy, in order to assess clinical response in a real-world setting and further validate the safe and appropriate use of SIR-Spheres

NCT ID: NCT05962450 Recruiting - Clinical trials for Hepatocellular Carcinoma

Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy

Start date: October 26, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to explore the efficacy and safety of autologous iNKT cells in patients with progressed hepatocellular carcinoma (HCC) after treatment with PD-1 antibody. The main question it aims to answer are: - the efficacy of autologous iNKT cells in patients with progressed HCC after treatment with PD-1 antibody. - the safety of autologous iNKT cells in patients with progressed HCC after treatment with PD-1 antibody. Participants will be randomized 1:1 to receive Regorafenib + PD-1 + iNKT cells (RPI group) or the treatment of Regorafenib + PD-1 (RP group). Researchers will compare RPI group and RP group to see whether the iNKT cells can achieve a better therapeutic effect on HCC patients with PD-1 resistance.

NCT ID: NCT05957640 Recruiting - Clinical trials for Unresectable Hepatocellular Carcinoma

Yttrium-90 Carbon Microspheres in Patients With Unresectable Hepatocellular Carcinoma

Start date: May 5, 2023
Phase: Phase 1
Study type: Interventional

To evaluate the efficacy and safety of yttrium-90 carbon microspheres in patients with unresectable hepatocellular carcinoma

NCT ID: NCT05954897 Recruiting - Clinical trials for Hepatocellular Carcinoma

Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma

Start date: September 1, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of lenvatinib, tislelizumab combined with RALOX regimen HAIC in advanced hepatocellular carcinoma.

NCT ID: NCT05953961 Recruiting - Clinical trials for Carcinoma, Hepatocellular

90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia

REALM
Start date: August 8, 2023
Phase: N/A
Study type: Interventional

This clinical trial will compare 1-year outcomes in patients with hypoalbuminemia and a new diagnosis of small, early-stage hepatocellular carcinoma (HCC) who are candidates for both 90-Yittrium Therasphere transarterial radioembolization (90Y) and microwave ablation (MWA). The study will determine whether treatment with 90Y lowers the risk of disease progression within the first year after diagnosis. Participants will be randomized to receive either first cycle 90Y or MWA and then proceed with standard of care.

NCT ID: NCT05953337 Recruiting - Clinical trials for Hepatocellular Carcinoma

Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)

Start date: September 21, 2023
Phase: N/A
Study type: Interventional

This is a prospective, multi-center, open-label study to evaluate the effectiveness and safety of Eye90 microspheres® in the treatment of subjects with unresectable Hepatocellular Carcinoma (HCC). Eye90 microspheres is a medical device containing yttrium-90 (Y-90), a radioactive material, and provides local radiation brachytherapy for the treatment of liver tumors.

NCT ID: NCT05937295 Recruiting - Clinical trials for Fibrolamellar Hepatocellular Carcinoma

FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined With Immune Checkpoint Inhibition

FusionVAC22
Start date: September 26, 2023
Phase: Phase 1
Study type: Interventional

The aim of this clinical trial is to evaluate the immunogenicity along with safety and toxicity as well as first efficacy of a DNAJB1-PRKACA fusion transcript-based peptide vaccine (Fusion-VAC-XS15) in combination with anti-programmed cell death-ligand 1 immune checkpoint inhibition (ICI) by Atezolizumab (TecentriqTM) in patients with Fibrolamellar hepatocellular carcinoma (FL-HCC) or other cancer entities carrying the DNAJB1-PRKACA fusion transcript.

NCT ID: NCT05935189 Recruiting - Clinical trials for Hepatocellular Carcinoma

Establishment of a Tissue Registry for Hepatocellular Carcinoma Specimens

TIR-HCC
Start date: July 1, 2023
Phase:
Study type: Observational [Patient Registry]

The goal of the study is to establish a cancer registry to facilitate research and assist in the identification of additional risk factors for hepatocellular carcinoma. The main objectives are: 1. provide a mechanism to store the information about subjects with hepatocellular carcinoma 2. use of tissue samples for translational/further research purposes